000			03244nam a22004457a 4500
008			220926s20222022 xxu||||| |||| 00| 0 eng d
022			_a0937-3462
024			_a10.1007/s00192-022-05271-w [doi]
024			_a10.1007/s00192-022-05271-w [pii]
040			_aOvid MEDLINE(R)
099			_a35788699
245			_aPrevalence of pelvic floor disorders, associations of endocrine therapy, and surgical intervention among breast cancer survivors.
251			_aInternational Urogynecology Journal. 2022 Jul 05
252			_aInt Urogynecol J Pelvic Floor Dysfunct. 2022 Jul 05
253			_aInternational urogynecology journal
260			_c2022
260			_fFY2023
260			_p2022 Jul 05
265			_saheadofprint
266			_d2022-09-26
501			_aAvailable online through MWHC library: 2010 - present
520			_aCONCLUSIONS: Rates of pelvic floor disorders were lower among breast cancer survivors compared to controls but rates of surgical intervention did not differ and were higher for some conditions among breast cancer survivors.
520			_aIMPLICATIONS FOR CANCER SURVIVORS: Screening for these disorders should be considered as part of routine survivorship care. Copyright © 2022. The International Urogynecological Association.
520			_aINTRODUCTION AND HYPOTHESIS: To evaluate prevalence of pelvic floor disorders, association of endocrine therapy with pelvic floor disorders, and rates of pelvic floor surgery among breast cancer survivors compared to matched controls without history of cancer.
520			_aMETHODS: This is a retrospective, cohort study using electronic medical record data from a ten-hospital regional healthcare system. A total of 19,483 women diagnosed with breast cancer between January 2008 and April 2020 were propensity score matched to 19,483 women without a history of cancer. Medical charts were abstracted for ICD-9 and ICD-10 codes for pelvic floor disorders, use of endocrine therapy, and CPT codes for pelvic floor surgeries and procedures.
520			_aRESULTS: Overall, the prevalence of pelvic floor disorders was lower among breast cancer survivors (8.8% vs. 22.6%, p < 0.001), and mean time to development of pelvic floor disorders among breast cancer survivors was 3 years. Selective estrogen receptor modulators and aromatase inhibitors were associated with pelvic organ prolapse and stress urinary incontinence, while estrogen antagonists were associated with urge urinary incontinence and lower urinary tract symptoms. Women with breast cancer had similar or higher rates of pelvic floor surgery compared to matched controls.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Health Research Institute
651			_aMedStar Washington Hospital Center
656			_aObstetrics and Gynecology/Female Pelvic Medicine and Reconstructive Surgery
657			_aJournal Article
700			_aDesale, Sameer
700			_aRichter, Lee A
700			_aWang, Haijun
700			_aZhang, Gongliang
790			_aDesale S, Pennycuff JF, Richter LA, Wang H, Zhang G
856			_uhttps://dx.doi.org/10.1007/s00192-022-05271-w _zhttps://dx.doi.org/10.1007/s00192-022-05271-w
942			_cART _dArticle
999			_c405 _d405